# Academic Paper Draft

## Title
**Empirical Evaluation of Polyglot Persistence in Scalable Pharmaceutical Supply Chain and Cold-Chain Tracking Systems**

## Abstract
Pharmaceutical supply chains require heterogeneous data guarantees: high-volume IoT time-series telemetry for cold-chain monitoring, complex graph traversals for provenance and counterfeit detection, document structures for regulatory compliance records, and low-latency in-memory caches for real-time tracking. This paper evaluates the performance, throughput, and operational trade-offs of a polyglot persistence architecture against traditional monolithic baselines.

---

## 📊 Figure 1: Multi-Tier Pharmaceutical Supply & Cold-Chain Lineage Graph

*(Generated from live Neo4j knowledge graph topology)*

```mermaid
graph LR
    subgraph Manufacturer_Tier ["Tier-1 Manufacturer"]
        M1["🏢 SHISEIDO AMERICAS CORP<br/>(Frankfurt, HE)<br/>GMP: Compliant"]
    end

    subgraph Product_Formulation ["Drug & Active Ingredients"]
        D1["💊 YESINTEK (Refrigerated 2-8°C)<br/>NDC: 0093-7679"]
        I1["🧪 USTEKINUMAB (mAb)"]
    end

    subgraph Distribution_Tier ["Intermediary Distribution Hub"]
        DIST1["🚚 AmerisourceBergen Northeast DC<br/>(Bethlehem, PA)<br/>Cold-Chain Certified: True"]
    end

    subgraph Dispensing_Tier ["Dispensing Healthcare Endpoint"]
        P1["🏥 30TH AVENUE PHARMACY INC<br/>(Astoria, NY)<br/>Cold Storage: Certified"]
    end

    M1 -->|PRODUCES| D1
    D1 -->|CONTAINS| I1
    M1 -->|SUPPLIES (Lead Time: 1d)| DIST1
    DIST1 -->|DISTRIBUTES_TO (Daily)| P1

    classDef mfr fill:#e1f5fe,stroke:#0288d1,stroke-width:2px;
    classDef drug fill:#f3e5f5,stroke:#7b1fa2,stroke-width:2px;
    classDef dist fill:#fff3e0,stroke:#f57c00,stroke-width:2px;
    classDef pharm fill:#e8f5e9,stroke:#388e3c,stroke-width:2px;

    class M1 mfr;
    class D1,I1 drug;
    class DIST1 dist;
    class P1 pharm;
```

---

## 📈 Figure 2: Real-Data Calibrated Disruption & Recovery Curve

*(Generated via `docs/charts/plot_shortage_disruption.py` calibrated against openFDA historical shortage records)*

```
==========================================================================================
   FIGURE 2: REAL FDA SHORTAGE DISRUPTION & RECOVERY CURVE (PAPER CANDIDATE)   
   Target Drug: Triamcinolone acetonide (DRUG-16714-268) | Evaluation Window: 90 Simulated Days
==========================================================================================
Day   | Status       | Shipments  | Avg Stock    | Stockouts  | Stock Level Trajectory
------------------------------------------------------------------------------------------
Day 1   | [SHORTAGE]   | 0          | 139.3        | 0          | #######################
Day 4   | [SHORTAGE]   | 0          | 83.8         | 24         | #############
Day 7   | [SHORTAGE]   | 1          | 50.2         | 53         | ########
Day 10  | [SHORTAGE]   | 1          | 23.9         | 91         | ###
Day 13  | [SHORTAGE]   | 0          | 13.1         | 112        | ##
Day 16  | [SHORTAGE]   | 1          | 6.9          | 130        | #
Day 19  | [SHORTAGE]   | 0          | 3.6          | 136        | (Depleted)
Day 22  | [SHORTAGE]   | 0          | 1.7          | 141        | (Severe Stockout Peak)
Day 25  | [NORMAL]     | 0          | 42.4         | 89         | #######
Day 28  | [NORMAL]     | 1          | 174.5        | 0          | #############################
Day 31  | [NORMAL]     | 0          | 110.1        | 0          | ##################
Day 34  | [NORMAL]     | 2          | 58.9         | 0          | #########
Day 37  | [NORMAL]     | 0          | 147.7        | 0          | ########################
==========================================================================================
```

High-resolution chart saved to [`docs/charts/shortage_disruption_curve.png`](file:///d:/project/polyglot-pharma-supply-chain/docs/charts/shortage_disruption_curve.png).

---

## Sections
1. Introduction & Problem Statement
2. Related Work
3. System Architecture & Polyglot Model
4. Data Pipeline & Stream Processing
5. Empirical Benchmarking & Results
6. Discussion & Limitations
7. Conclusion
